期刊文献+

普伐他汀对不稳定型心绞痛合并高脂血症患者临床及血液流变学的影响 被引量:2

Effect of pravastatin on the clinical and hemorheology in patients with unstable angina and hyperlipidemia
下载PDF
导出
摘要 目的观察普伐他汀对不稳定型心绞痛并高脂血症患者临床及血液流变学的影响。方法120例不稳定型心绞痛并高脂血症患者随机分为治疗组和对照组,各60例。对照组给予硝酸酯类,阿司匹林等常规治疗。治疗组在对照组常规治疗的基础上加普伐他汀口服,20mg,每晚服用。两组均连续治疗6个月。观察两组治疗前后临床疗效及血液流变学等指标的变化。结果治疗后治疗组心绞痛及心电图总有效率明显高于对照组(P〈0.05);治疗组总胆固醇(TC)、甘油三酪(TG)、低密度脂蛋白胆固醇(LDL~C)非常显著低于对照组(P〈0.01);治疗组全血低切黏度明显低于对照组(P〈0.05)。结论普伐他汀能有效调整血脂代谢,改善血液流变学指标,对不稳定型心绞痛并高脂血症的疗效确切,且安全性好。 Objective To observe effect of pravastatin on the clinical and hemorheology in patients' with wrstable angina and hyper lipid emia. Methods 120 patients with unstable angina and hyperlipemia were randomly divided into the treatment group (60 cases) and the control group (60 cases), the control group was given nitrates, aspirin and other conventional treatment. The treatment group increased pravastatin oral on the basis conventional therapy of the control group,20 rag, once every night. Two groups were continuously treated for 6 months. Observed two groups the clinical efficacy and hemorileology changes in such indicators before and aler treatment. Results After treatment, the angina pectoris and ECG total effective rate of the treatment group were higher than those of the control group ( P 〈 0. 05 ) ; TC, TG, LDL - C of the treatment group were significantly lower than those of the control group ( P 〈 0. 01 ) ; The whole blood low shear viscosity of the treatmentgroup were significantly lower than those of the control group ( P 〈 0. 05 ). Conclusion Pravastatin can effectively adjust the lipid metabolism, improve hemurheology indicators for unstable angina and hyperlipidemia accurate and safe.
作者 彭波涛
出处 《中国医学创新》 CAS 2010年第5期81-83,共3页 Medical Innovation of China
关键词 不稳定型心绞痛 高脂血症 血液流变学 普伐他汀 Unstable angina Hyperlipidemia Hemorheology Pravastatin
  • 相关文献

参考文献5

二级参考文献70

  • 1Simes J, Furberg CD, Braunwald E, Davis BR, Ford I, Tonkin A, et al.Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels.The Prospective Pravastatin Pooling project.Eur Heart J, 2002, 23 (3):207-215
  • 2Scandinavian Simvastatin Survival Study Group.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study (4S).Lancet, 1994, 344:1 383-389
  • 3Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al.Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels:results of AFCAPS/TexCAPS.Air Force/Texas Coronary Atherosclerosis Prevention Study.J Am Med Assoc, 1998, 279 (20):1 615-622
  • 4Plutzky J, Ridker PM.Statins for Stroke:The Second Story? Circulation, 2002, 103 (3):348-350
  • 5Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al.Effect of pravastatin on outcomes after cardiac transplantation.N Engl J Med, 1995, 333 (10):621-627
  • 6Wenke K, Meiser B, Thiery J, Nagel D, Scheidt WV, Steinbeck G, et al.Simvastatin reduces graft vessel disease and mortality after heart transplantation.Circulation, 1997, 96 (5):1 398-402
  • 7Strandberg TE, Vanhanen H, Tikkanen MJ.Effect of statins on C-reactive protein with coronary artery disease.Lancet, 1999, 353(9147):118-119
  • 8Rider PM, Rifai N, Pfeffer M, Sacks F, Braunwald E.For the cholesterol and recurrent event (CARE) investigators.Long-term effects of pravastatin on plasma concentration of C-reactive protein.Circulation, 1999, 100 (3):230-235
  • 9Albert MA, Staggers J, Chew P, Rider PM.The pravastatin inflammation CRP evaluation (PRINCE):rationale and design.Am Heart J, 2001, 141 (6):893-898
  • 10Albert MA, Danielson E, Rifai N, Ridker PM.Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation / CRP Evaluation (PRINCE):A randomize trial and cohort study.J Am Med Assoc, 2001, 286 (1):64-70

共引文献136

同被引文献6

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部